Shares of Health Care sector company Edwards Lifesciences moved -0.4% today, and are now trading at a price of $76.03. The Large-Cap stock's daily volume was 397,098 compared to its average volume of 4,435,247. The S&P 500 index returned a 0.0% performance.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company is based in Irvine and has 15,800 full time employees. Its market capitalization is $45,148,999,680.
30 analysts are following Edwards Lifesciences and have set target prices ranging from $72.0 to $100.0 per share. On average, they have given the company a rating of buy. At today's prices, EW is trading -12.78% away from its average analyst target price of $87.16 per share.
Over the last year, EW's share price has increased by 16.7%, which represents a difference of -1.0% when compared to the S&P 500. The stock's 52 week high is $83.0 per share whereas its 52 week low is $64.01. Edwards Lifesciences's average free cash flow over the last 5 years has been $814.73 Million, but they have been decreasing at an average rate of -18.1%. This may prove a challenge to the long term sustainability of the stock's upwards trend.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 542,300 | 252,400 | 289,900 | -54.9 |
| 2023 | 895,800 | 253,000 | 642,800 | -33.98 |
| 2022 | 1,218,200 | 244,600 | 973,600 | -30.77 |
| 2021 | 1,732,100 | 325,800 | 1,406,300 | 117.26 |
| 2020 | 1,054,300 | 407,000 | 647,300 | -30.29 |
| 2019 | 1,182,900 | 254,400 | 928,500 |
